Track topics on Twitter Track topics that are important to you
The European Patent Office (EPO) has told MilliporeSigma it intends to grant approval of its patent application covering the company's CRISPR technology used in a genomic integration method for eukaryotic cells—the second key patent awarded in Europe covering the gene-editing technology. MilliporeSigma, the life science business of Merck KGaA, said the EPO has issued a “Notice of Intention to Grant” a broad patent for the company’s CRISPR (clustered regularly interspaced short palindromic repeats) genomic integration technology. The patent would be along the lines of one awarded to MilliporeSigma in Australia in June. That patent covers chromosomal integration or cutting of the chromosomal sequence of eukaryotic cells and insertion of an external or donor DNA sequence into those cells using CRISPR. “The present invention provides RNA-guided endonucleases, which are engineered for expression in eukaryotic cells or embryos, and methods of using the RNA-guided endonuclease for targeted genome ...
Original Article: MilliporeSigma to Be Granted European Patent for CRISPR TechnologyNEXT ARTICLE
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...